Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
Aim of this study will evaluate the efficacy and safety of tislelizumab in combination with
lenalidomide in in patients with relapsed or refractory Elderly Patients with non-GCB Diffuse
Large B Cell Lymphoma